nach oben

Current Diabetes Reports

Erschienen in:

22.05.2023

Is Diabetes Mellitus a Predisposing Factor for Helicobacter pylori Infections?

verfasst von: Om Saswat Sahoo, Rhiti Mitra, Arghyadeep Bhattacharjee, Samarjit Kar, Oindrilla Mukherjee

Erschienen in: Current Diabetes Reports | Ausgabe 8/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This review aims to analyse the consistency of reports suggesting the role of Diabetes Mellitus in the pathogenesis of Helicobacter pylori (H. pylori).

Recent Findings

There have been numerous controversies citing the prevalence of H. pylori infections in patients suffering from type 2 diabetes mellitus (T2DM). This review investigates the possible crosstalk between H. pylori infections and T2DM and also designs a meta-analysis to quantify the association. Subgroup analyses have also been conducted to deduce factors like geography and testing techniques, in playing a role in stratification analysis.

Summary

Based on a scientific literature survey and meta-analysis of databases from 1996 to 2022, a trend towards more frequent H. pylori infections in patients with diabetes mellitus was observed. The highly diversified nature of H. pylori infections across age, gender, and geographical regions requires large interventional studies to evaluate its long-term association with diabetes mellitus. Further possible linkage of the prevalence of diabetes mellitus concomitant with that of H. pylori infected patients has also been delineated in the review.

Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract [Internet]. Elsevier Ireland Ltd; 2019;157:107843. https://doi.org/10.1016/j.diabres.2019.107843

Zhou Z, Sun B, Yu D, Zhu C. Gut microbiota: an important player in type 2 diabetes mellitus. Front Cell Infect Microbiol. 2022;12:1–15.

Ojetti V, Migneco A, Silveri N, Ghirlanda G, Gasbarrini G, Gasbarrini A. The role of H. pylori infection in diabetes. Curr Diabetes Rev. 2005;1:343–7.PubMedCrossRef

Tawfeeq R, Amin Z, Nuraddin S, Jalal A, Hama BS. Relationship between type II diabetes mellitus and Helicobacter pylori infection in Erbil city. Zanco J Med Sci. 2019;23:43–50.

Porras C, Nodora J, Sexton R, Ferreccio C, Jimenez S, Dominguez RL, et al. Epidemiology of helicobacter pylori infection in six Latin American countries (SWOG Trial S0701). Cancer Causes Control. 2013;24:209–15.PubMedCrossRef

Suzuki RB, Cola RF, Cola LTB, Ferrari CG, Ellinger F, Therezo AL, et al. Different risk factors influence peptic ulcer disease development in a Brazilian population. World J Gastroenterol. 2012;18:5404–11.PubMedPubMedCentralCrossRef

Den Hoed CM, Van Eijck BC, Capelle LG, Van Dekken H, Biermann K, Siersema PD, et al. The prevalence of premalignant gastric lesions in asymptomatic patients: predicting the future incidence of gastric cancer. Eur J Cancer [Internet]. Elsevier Ltd; 2011;47:1211–8. https://doi.org/10.1016/j.ejca.2010.12.012

Toh JWT, Wilson RB. Pathways of gastric carcinogenesis, helicobacter pylori virulence and interactions with antioxidant systems, vitamin C and phytochemicals. Int J Mol Sci. 2020;21:1–45.CrossRef

Chuang CH, Sheu BS, Yang HB, Kao AW, Cheng HC, Yao WJ. Hypergastrinemia after Helicobacter pylori infection is associated with bacterial load and related inflammation of the oxyntic corpus mucosa. J Gastroenterol Hepatol. 2004;19:988–93.PubMedCrossRef

10.

Censini S, Stein M, Covacci A. Cellular responses induced after contact with Helicobacter pylori. Curr Opin Microbiol. 2001;4:41–6.PubMedCrossRef

11.

Tripathi BK, Srivastava AK. Diabetes mellitus: complications and therapeutics. Med Sci Monit. 2006;12:130–48.

12.

Unnikrishnan R, Anjana RM, Mohan V. Diabetes mellitus and its complications in India. Nat Rev Endocrinol Nature Publishing Group. 2016;12:357–70.CrossRef

13.

HosseininasabNodoushan S, Nabavi A. The interaction of Helicobacter pylori infection and type 2 diabetes mellitus. Adv Biomed Res. 2019;8:15.

14.

Gulcelik NE, Kaya E, Demirbas B, Culha C, Koc G, Ozkaya M, et al. Helicobacter pylori prevalence in diabetic patients and its relationship with dyspepsia and autonomic neuropathy. J Endocrinol Invest. 2005;28:214–7.PubMedCrossRef

15.

Gentile S, Turco S, Oliviero B, Torella R. The role of autonomic neuropathy as a risk factor of Helicobacter pylori infection in dyspeptic patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 1998;42:41–8.PubMedCrossRef

16.

Kouitcheu Mabeku LB, Noundjeu Ngamga ML, Leundji H. Helicobacter pylori infection, a risk factor for type 2 diabetes mellitus: a hospital-based cross-sectional study among dyspeptic patients in Douala-Cameroon. Sci Rep [Internet]. Nature Publishing Group UK; 2020;10:1–11. https://doi.org/10.1038/s41598-020-69208-3

17.

Bazmamoun H, Rafeey M, Nikpouri M, Ghergherehchi R. Helicobacter pylori infection in children with type 1 diabetes mellitus: a case-control study. J Med Sci. 2016;16:68–71.

18.

Papamichael KX, Papaioannou G, Karga H, Roussos A, Mantzaris GJ. Helicobacter pylori infection and endocrine disorders: is there a link? World J Gastroenterol. 2009;15:2701–7.PubMedPubMedCentralCrossRef

19.

Marrollo M, Latella G, Melideo D, Storelli E, Iannarelli R, Stornelli P, et al. Increased prevalence of Helicobacter pylori in patients with diabetes mellitus. Dig Liver Dis. 2001;33:21–9.PubMedCrossRef

20.

Jones KL, Wishart JM, Berry M, Russo A, Xia HHX, Talley NJ, et al. Helicobacter pylori infection is not associated with delayed gastric emptying or upper gastrointestinal symptoms in diabetes mellitus. Dig Dis Sci. 2002;47:704–9.PubMedCrossRef

21.

Ibrahim A, Zaher T, Ghonemy TA, Al E. Impact of cytotoxin-associated gene a of Helicobacter pylori strains on microalbuminuria in type 2 diabetes. Saudi J Kidney Dis Transplant. 2010;21:694–700.

22.

Abdollahi L, Molabashi Z, Azami M, Salehi R, Hejazi SH, Abdali N. Is there a pathological relationship between microalbuminuria and Helicobacter pylori vacA and cagA genes in type 2 diabetic patients? Comp Clin Path. 2018;27:1–6.CrossRef

23.

Devrajani BR, Shah SZA, Soomro AA, Devrajani T. Type 2 diabetes mellitus: a risk factor for Helicobacter pylori infection: a hospital based case-control study. Int J Diabetes Dev Ctries. 2010;30:22–6.PubMedPubMedCentralCrossRef

24.

Zhou X, Zhang C, Wu J, Zhang G. Association between Helicobacter pylori infection and diabetes mellitus: a meta-analysis of observational studies. Diabetes Res Clin Pract [Internet]. Elsevier Ireland Ltd; 2013;99:200–8. https://doi.org/10.1016/j.diabres.2012.11.012

25.

Wang F, Liu J, Lv Z. Association of Helicobacter pylori infection with diabetes mellitus and diabetic nephropathy: a meta-analysis of 39 studies involving more than 20,000 participants. Scand J Infect Dis. 2013;45:930–8.PubMedCrossRef

26.

Han X, Li Y, Wang J, Liu B, Hu H, Li X, et al. Helicobacter pylori infection is associated with type 2 diabetes among a middle- and old-age Chinese population. Diabetes Metab Res Rev [Internet]. 2016;32:95–101. http://libweb.anglia.ac.uk/

27.

Li JZ, Li JY, Wu TF, Xu JH, Huang CZ, Cheng D, et al. Helicobacter pylori infection is associated with type 2 diabetes, not type 1 diabetes: an updated meta-analysis. Gastroenterol Res Pract. 2017;2017.

28.

Shi Y, Duan JY, Liu DW, Qiao YJ, Han QX, Pan SK, et al. Helicobacter pylori infection is associated with occurrence of proteinuria in type 2 diabetes patients: a systemic review and meta-analysis. Chin Med J (Engl). 2018;131:2734–40.PubMedCrossRef

29.

Mansori K, Dehghanbanadaki H, Naderpour S, Rashti R, Moghaddam AB, Moradi Y. A systematic review and meta-analysis of the prevalence of Helicobacter pylori in patients with diabetes. Diabetes Metab Syndr Clin Res Rev [Internet]. Elsevier Ltd; 2020;14:601–7. https://doi.org/10.1016/j.dsx.2020.05.009

30.

Gravina AG, Priadko K, Ciamarra P, Granata L, Facchiano A, Miranda A, et al. Extragastric manifestations of Helicobacter pylori infection. J Clin Med. 2020;9:3887.PubMedPubMedCentralCrossRef

31.••

Song X, Cai C, Jin Q, Chen X, Yu C. The efficacy of Helicobacter pylori eradication in diabetics and its effect on glycemic control: a systematic review and meta-analysis. Helicobacter. 2021;26:1–15. Acknowledged the importance of H. pylori eradication in regulation of glycemic control in patients with Diabetes.

32.

Gasbarrini A, Ojetti V, Pitocco D, Armuzzi A, GentiloniSilveri N, Pola P, et al. Efficacy of different Helicobacter pylori eradication regimens in patients affected by insulin-dependent diabetes mellitus. Scand J Gastroenterol. 2000;35:260–3.PubMedCrossRef

33.

Malecki M, Bień AI, Galicka-Latata D, Stachura J, Sieradzki J. The prevalence of Helicobacter pylori infection and types of gastritis in diabetic patients The Krakow study. Exp Clin Endocrinol Diabetes. 1996;104:365–9.

34.

Ko GTC, Chan FKL, Chan W-B, Sung JJY, Al E. Helicobacter pylori infection in Chinese subjects with type 2 diabetes. Endocr Res. 2001;27:171–7.PubMedCrossRef

35.

Senturk O, Canturk Z, Çetinarslan B, Ercin C, Hulagu S, Canturk NZ. Prevalence and comparisons of five different diagnostic methods for Helicobacter pylori in diabetic patients. Endocr Res. 2001;27:179–89.PubMedCrossRef

36.

Demir M, Gokturk HS, Ozturk NA, Kulaksizoglu M, Serin E, Yilmaz U. Helicobacter pylori prevalence in diabetes mellitus patients with dyspeptic symptoms and its relationship to glycemic control and late complications. Dig Dis Sci. 2008;53:2646–9.PubMedCrossRef

37.

Hamed SA, Amine NF, Galal GM, Helal SR, Tag El-Din LM, Shawky OA, et al. Vascular risks and complications in diabetes mellitus: the role of Helicobacter pylori infection. J Stroke Cerebrovasc Dis. 2008;17:86–94.PubMedCrossRef

38.

Ugwu N, Ugwuja E, Ejikeme B, Obeka NC. Helicobacter pylori seropositivity in Nigerians with type 2 diabetes mellitus. Internet J Trop Med. 2008;4.

39.

Lazaraki G, Kountouras J, Metallidis S, Vrettou E, Alevizos M, Tzioufa V, et al. Endothelial nitric oxide synthase (eNOS) is not upregulated in gastric mucosa of Helicobacter pylori (H. pylori)-positive patients with type 2 diabetes mellitus. Dig Liver Dis. 2009;41:253–62.PubMedCrossRef

40.

Yang GH, Wu JS, Yang YC, Huang YH, Lu FH, Chang CJ. Gastric Helicobacter pylori infection associated with risk of diabetes mellitus, but not prediabetes. J Gastroenterol Hepatol. 2014;29:1794–9.PubMedCrossRef

41.

Bajaj S, Rekwal L, Misra S, Misra V, Yadav R, Srivastava A. Association of Helicobacter pylori infection with type 2 diabetes. Indian J Endocrinol Metab. 2014;18:694.PubMedPubMedCentralCrossRef

42.

Vafaeimanesh J, Parham M, Bagherzadeh M. Helicobacter pylori infection prevalence: is it different in diabetics and nondiabetics? Indian J Endocrinol Metab. 2015;19:364–8.PubMedPubMedCentralCrossRef

43.

Saeed CH. Prevalence of Helicobacter pylori infection in patients with type 2 diabetic. Karbala J Med. 2021;14:2397–403.

44.

Nami A, Ez Y, Ah AHE, Ama S, Hm K. Helicobacter pylori infections among patients with type 2 diabetes mellitus in Benghazi. Libya Japanese J Gastroenterol Hepatol. 2022;8:1–7.

45.

Al-Khafaf AH, Al-Rawi NF, Ibrahem HA, Hussein NR. Association of Helicobacter pylori infection with type 2 diabetic patients in Dohuk Governorate. Iraq Iraqi J Sci. 2022;63:62–9.

46.

Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006;116:1793–801.PubMedPubMedCentralCrossRef

47.

Itani SI, Ruderman NB, Schmieder F, Boden G. Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IκB-α. Diabetes. 2002;51:2005–11.PubMedCrossRef

48.

Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813–20.PubMedCrossRef

49.

Grote VA, Rohrmann S, Nieters A, Dossus L, Tjønneland A, Halkjær J, et al. Diabetes mellitus, glycated haemoglobin and C-peptide levels in relation to pancreatic cancer risk: a study within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Diabetologia. 2011;54:3037–46.PubMedCrossRef

50.

Jones EA. Progress report Diabetes and the gut. Gut. 1978;19:1153–62.CrossRef

51.

Atkinson M, Hosking DJ. Gastrointestinal complications of diabetes mellitus. Clin Gastroenterol. 1983;12:633–50.PubMedCrossRef

52.

Borody T, Ren Z, Pang G, Clancy R. Impaired host immunity contributes to Helicobacter pylori eradication failure. Am J Gastroenterol. 2002;97:3032–7.PubMedCrossRef

53.

Williams J, Mobarhan S. A Critical interaction: leptin and ghrelin. Nutr Rev. 2003;61:391–3.PubMedCrossRef

54.

Shintani M, Ogawa Y, Ebihara K, Aizawa-abe M, Miyanaga F, Takaya K, et al. Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. Diabetes. 2001;50:227–32.PubMedCrossRef

55.

Verhulst PJ, Depoortere I. Ghrelin’s second life: from appetite stimulator to glucose regulator. World J Gastroenterol. 2012;18:3183–95.PubMedPubMedCentral

56.

Gerich JE. Somatostatin and diabetes. Am J Med. 1981;70:619–26.PubMedCrossRef

57.

Sindhu RK, Koo JR, Roberts CK, Vaziri ND. Dysregulation of hepatic superoxide dismutase, catalase and glutathione peroxidase in diabetes: response to insulin and antioxidant therapies. Clin Exp Hypertens. 2004;26:43–53.PubMedCrossRef

58.

Sies H, Sharov VS, Klotz LO, Briviba K. Glutathione peroxidase protects against peroxynitrite-mediated oxidations: a new function for selenoproteins as peroxynitrite reductase. J Biol Chem [Internet]. Â© 1997 ASBMB. Currently published by Elsevier Inc; originally published by American Society for Biochemistry and Molecular Biology. 1997;272:27812–7. https://doi.org/10.1074/jbc.272.44.27812

59.

Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat. Rev. Cancer. 2008. 915–28.

60.

Mardilovich K, Pankratz SL, Shaw LM. Expression and function of the insulin receptor substrate proteins in cancer. Cell Commun Signal. 2009;7:1–15.CrossRef

61.

Clemmons DR, Maile LA, Ling Y, Yarber J, Busby WH. Role of the integrin αVβ3 in mediating increased smooth muscle cell responsiveness to IGF-I in response to hyperglycemic stress. Growth Horm IGF Res. 2007;17:265–70.PubMedPubMedCentralCrossRef

62.

Feldman M, Corbett DB, Ramsey EJ, Walsh JH, Richardson CT. Abnormal gastric function in longstanding, insulin-dependent diabetic patients Gastroenterology [Internet]. Am Gastroenterol Assoc. 1979;77:12–7. https://doi.org/10.1016/S0016-5085(79)80003-7.CrossRef

63.

Isomoto H, Ueno H, Nishi Y, Wen CY, Nakazato M, Kohno S. Impact of Helicobacter pylori infection on ghrelin and various neuroendocrine hormones in plasma. World J Gastroenterol. 2005;11:1644–8.PubMedPubMedCentralCrossRef

64.

Bell DSH. Metformin-induced vitamin B12 deficiency presenting as a peripheral neuropathy. South Med J. 2010;103:265–7.PubMedCrossRef

65.

Ahmed MA. Metformin and vitamin B12 deficiency: where do we stand? J Pharm Pharm Sci. 2016;19:382–98.PubMedCrossRef

66.

Kozyraki R, Cases O. Vitamin B12 absorption: mammalian physiology and acquired and inherited disorders. Biochimie [Internet]. Elsevier Masson SAS; 2013;95:1002–7. https://doi.org/10.1016/j.biochi.2012.11.004

67.

Baj J, Forma A, Flieger W, Morawska I, Michalski A, Buszewicz G, et al. Helicobacter pylori infection and extragastric diseases—a focus on the central nervous system. Cells. 2021;10:1–17.CrossRef

68.

Xia H, et al. Helicobacter pylori infection is not associated with diabetes mellitus, nor with upper gastrointestinal symptoms in diabetes mellitus. Am J Gastroenterol. 2001;96:1039–46.PubMedCrossRef

69.

Anastasios R, Goritsas C, Papamihail C, Trigidou R, Garzonis P, Ferti A. Helicobacter pylori infection in diabetic patients: prevalence and endoscopic findings. Eur J Intern Med. 2002;13:376–9.PubMedCrossRef

70.

Woodward M, Morrison C, McColl K. An investigation into factors associated with Helicobacter pylori infection. J Clin Epidemiol. 2000;53:175–81.PubMedCrossRef

71.

Vazeou A, Papadopoulou A, Booth IW, Bartsocas CS. Prevalence of gastrointestinal symptoms in children and adolescents with type 1 diabetes. Diabetes Care. 2001;24:962–4.PubMedCrossRef

72.

Alzahrani A, Al Zaidi A, Alzahrani S, Binmahfouz S, Farahat F. Association between type 2 diabetes mellitus and Helicobacter pylori infection among Saudi patients attending National Guard Primary Health Care centers in the Western Region, 2018. J Fam Community Med. 2020;27:8–14.

73.

Hussain MJ, Alviggi L, Millward BA, Leslie RDG, Pyke DA, Vergani D. Evidence that the reduced number of natural killer cells in type 1 (insulin-dependent) diabetes may be genetically determined. Diabetologia. 1987;30:907–11.PubMedCrossRef

74.

Tamura T, Morita E, Kawai S, Sasakabe T, Sugimoto Y, Fukuda N, et al. No association between Helicobacter pylori infection and diabetes mellitus among a general Japanese population: a cross-sectional study. Springerplus. Springer International Publishing; 2015;4.

75.

Jafarzadeh A, Rezayati MT, Nemati M. Helicobacter pylori seropositivity in patients with type 2 diabetes mellitus in south-east of Iran. Acta Med Iran. 2013;51:892–6.PubMed

76.

Pyo JH, Lee H, Choi SC, Cho SJ, Choi YH, Min YW, et al. Lack of association between past Helicobacter pylori infection and diabetes: a two-cohort study. Nutrients. 2019;11:1–10.CrossRef

77.

Man S, Ma Y, Jin C, Lv J, Tong M, Wang B, et al. Association between Helicobacter pylori infection and diabetes: a cross-sectional study in China. J Diabetes Res. 2020;2020.

78.

Akopyants NS, Clifton SW, Kersulyte D, Crabtree JE, Youree BE, Reece CA, et al. Analyses of the cag pathogenicity island of Helicobacter pylori. Mol Microbiol. 1998;28:37–53.PubMedCrossRef

79.

Cover TL, Blanke SR. Helicobacter pylori VacA, a paradigm for toxin multifunctionality. Nat Rev Microbiol. 2005;3:320–32.PubMedCrossRef

80.

Omori K, Mitsuhashi M, Ishiyama K, Nair I, Rawson J, Todorov I, et al. mRNA of the pro-apoptotic gene BBC3 serves as a molecular marker for TNF-α-induced islet damage in humans. Diabetologia. 2011;54:2056–66.PubMedCrossRef

81.

Allison CC, Ferrand J, McLeod L, Hassan M, Kaparakis-Liaskos M, Grubman A, et al. Nucleotide oligomerization domain 1 enhances IFN-γ signaling in gastric epithelial cells during Helicobacter pylori infection and exacerbates disease severity. J Immunol. 2013;190:3706–15.PubMedCrossRef

82.

Beydoun MA, Dore GA, Canas JA, Beydoun HA, Zonderman AB. Helicobacter pylori seropositivity’s association with markers of iron, 1-carbon metabolism, and antioxidant status among US adults: a structural equations modeling approach. PLoS One. 2015;10:1–16.CrossRef

83.

Covantev S, Timbalari E, Florea N. Helicobacter pylori and type 2 diabetes mellitus: searching for the links. Russ Open Med J. 2016;5:1–5.CrossRef

84.••

Gravina AG, Zagari RM, De MC, Romano L, Loguercio C, Romano M. Helicobacter pylori and extragastric diseases: a review. World J Gastroenterol. 2018;24:3204–21. A detailed study on the association of Helicobacter pylori with diseases, which do not concern the bacteria's pathogenesis.

85.

He C, Yang Z, Lu NH. Helicobacter pylori infection and diabetes: is it a myth or fact? World J Gastroenterol. 2014;20:4607–17.PubMedPubMedCentralCrossRef

86.

Dai YN, Yu WL, Zhu HT, Ding JX, Yu CH, Li YM. Is Helicobacter pylori infection associated with glycemic control in diabetics? World J Gastroenterol. 2015;21:5407–16.PubMedPubMedCentralCrossRef

87.

King GL. The role of inflammatory cytokines in diabetes and its complications. J Periodontol. 2008;79:1527–34.PubMedCrossRef

88.

Jeon CY, Haan MN, Cheng C, Clayton ER, Mayeda ER, Miller JW, et al. Helicobacter pylori infection is associated with an increased rate of diabetes. Diabetes Care. 2012;35:520–5.PubMedPubMedCentralCrossRef

89.

Thorand B, Löwel H, Schneider A, Kolb H, Meisinger C, Fröhlich M, et al. C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men. Arch Intern Med. 2003;163:93.PubMedCrossRef

90.

Freeman DJ, Norrie J, Caslake MJ, Gaw A, Ford I, Lowe GDO, et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the west of Scotland coronary prevention study. Diabetes. 2002;51:1596–600.PubMedCrossRef

91.

Manco M, Putignani L, Bottazzo GF. Gut microbiota, lipopolysaccharides, and innate immunity in the pathogenesis of obesity and cardiovascular risk. Endocr Rev. 2010;31:817–44.PubMedCrossRef

92.

Lassenius MI, Pietiläinen KH, Kaartinen K, Pussinen PJ, Syrjänen J, Forsblom C, et al. Bacterial endotoxin activity in human serum is associated with dyslipidemia, insulin resistance, obesity, and chronic inflammation. Diabetes Care. 2011;34:1809–15.PubMedPubMedCentralCrossRef

93.

Zhou X, Liu W, Gu M, Zhou H, Zhang G. Helicobacter pylori infection causes hepatic insulin resistance by the c-Jun/miR-203/SOCS3 signaling pathway. J Gastroenterol [Internet]. Springer Japan; 2015;50:1027–40. https://doi.org/10.1007/s00535-015-1051-6

94.

Chen Y, Blaser MJ. Association between gastric helicobacter pylori colonization and glycated hemoglobin levels. J Infect Dis. 2012;205:1195–202. A detailed study on the association of Helicobacter pylori with diseases, which do not concern the bacteria's pathogenesis

95.

Hsieh MC, Wang SSW, Hsieh YT, Kuo FC, Soon MS, Wu DC. Helicobacter pylori infection associated with high HbA1c and type 2 diabetes. Eur J Clin Invest. 2013;43:949–56.PubMedCrossRef

96.

Chen J, Xing Y, Zhao L, Ma H. The association between Helicobacter pylori infection and glycated hemoglobin A in diabetes: a meta-analysis. J Diabetes Res. 2019;2019.

97.

Rahman A, Cope MB, Sarker SA, Garvey WT, Chaudhury HS, Khaled MA. Helicobacter pylori infection and inflammation: implications for pathophysiology of diabetes mellitus and coronary heart disease. J Life Sci. 2009;1:45–50.PubMedPubMedCentral

98.

Aydemir S, Bayraktaroglu T, Sert M, Sokmen C, Atmaca H, Mungan G, et al. The effect of Helicobacter pylori on insulin resistance. Dig Dis Sci. 2005;50:2090–3.PubMedCrossRef

99.

Eshraghian A, Hashemi SA, Jahromi AH, Eshraghian H, Masoompour SM, Davarpanah MA, et al. Helicobacter pylori infection as a risk factor for insulin resistance. Dig Dis Sci. 2009;54:1966–70.PubMedCrossRef

100.

Kato M, Toda A, Yamamoto-Honda R, Arase Y, Sone H. Association between Helicobacter pylori infection, eradication and diabetes mellitus. J Diabetes Investig. 2019;10:1341–6.PubMedPubMedCentralCrossRef

101.

Chen YY, Fang WH, Wang CC, Kao TW, Chang YW, Wu CJ, et al. Helicobacter pylori infection increases risk of incident metabolic syndrome and diabetes: a cohort study. PLoS ONE. 2019;14:1–11.

102.

Bassaganya-Riera J, Dominguez-Bello MG, Kronsteiner B, Carbo A, Lu P, Viladomiu M, et al. Helicobacter pylori colonization ameliorates glucose homeostasis in mice through a PPAR γ-dependent mechanism. PLoS One. 2012;7.

Titel: Is Diabetes Mellitus a Predisposing Factor for Helicobacter pylori Infections?
verfasst von: Om Saswat Sahoo
Rhiti Mitra
Arghyadeep Bhattacharjee
Samarjit Kar
Oindrilla Mukherjee
Publikationsdatum: 22.05.2023
Verlag: Springer US
Erschienen in: Current Diabetes Reports / Ausgabe 8/2023
Print ISSN: 1534-4827
Elektronische ISSN: 1539-0829
DOI: https://doi.org/10.1007/s11892-023-01511-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

11.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Im Battle of Experts traten zwei Experten auf dem Diabeteskongress gegeneinander an: Die eine vertrat die Auffassung „Sport statt Spritze“ bei Adipositas und Typ-2-Diabetes, der andere forderte „Spritze statt Sport!“ Am Ende waren sie sich aber einig: Die Kombination aus beidem erzielt die besten Ergebnisse.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen